ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 54.89B
Enterprise Value 34.91B
Trailing P/E N/A
Forward P/E 1-20.22
PEG Ratio (5 yr expected) 1-0.74
Price/Sales (ttm)N/A
Price/Book (mrq)12.21
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 0.85
52-Week Change 352.38%
S&P500 52-Week Change 33.49%
52 Week High 3133.96
52 Week Low 353.21
50-Day Moving Average 3111.76
200-Day Moving Average 3117.36

Share Statistics

Avg Vol (3 month) 3274.24k
Avg Vol (10 day) 3235.76k
Shares Outstanding 547.55M
Float 35.57M
% Held by Insiders 122.43%
% Held by Institutions 139.41%
Shares Short (Aug 15, 2019) 42.37M
Short Ratio (Aug 15, 2019) 410.92
Short % of Float (Aug 15, 2019) 4N/A
Short % of Shares Outstanding (Aug 15, 2019) 44.99%
Shares Short (prior month Jul 15, 2019) 41.96M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in EUR.

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-20.03%
Return on Equity (ttm)-35.44%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)17,738.90%
Gross Profit (ttm)10.58M
EBITDA N/A
Net Income Avi to Common (ttm)N/A
Diluted EPS (ttm)-3.87
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)5.38
Current Ratio (mrq)11.59
Book Value Per Share (mrq)8.43

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A